Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled European comments to ATA medullary thyroid cancer guidelines

Thyroid Research

Volumn 6, Issue SUPPL.1, 2013, Pages

  Jarza̧b, Barbara ^a   Król, Aleksandra ^a   Hasse Lazar, Kornelia ^a   Jurecka Lubieniecka, Beata ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875292969     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-6-S1-S11     Document Type: Review

References (19)

1. Medullary thyroid cancer: management guidelines of the American Thyroid Association. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr, Thyroid 2009 19 6 565 612 10.1089/thy.2008.0403 19469690
2. ETA-CRN. http://eta-crn.eurothyroid.com/meeting-2009.php
3. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC. Elisei R, Romei C, Thyroid Research 2013 6 Suppl 1 2
4. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, Eur J Endocrinol 2006 154 6 787 803 10.1530/eje.1.02158 16728537 (Pubitemid 43997716)
5. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Scheuba C, Kaserer K, Weinhausl A, Pandev R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA, Niederle B, Surgery 1999 126 1089 96 10.1067/msy.2099.102268 10598192
6. Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmeyer C, Haas OA, Niederle B, Endocrine Related Cancer 2009 26 243 253 18987170
7. The value of intraoperative pentagastrin testing in medullary thyroid cancer. Scheuba C, Bieglmayer C, Asari R, Kaczirek K, Izay B, Kaserer K, Niederle B, Surgery 2007 141 166 171 10.1016/j.surg.2006.12.006 17263971 (Pubitemid 46149883)
8. Sporadic versus familial medullary thyroid microcarcinoma: a histopatological study of 50 consecutive patients. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Haas O, Vierhapper H, Niederle B, Am J Surg Pathol 2001 25 10 124 1251 11688458
9. Medullary thyroid microcarcinoma recommendations for treatment-a single-center experience. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, Niederle B, Surgery 2007 142 1003 1010 discussion 1010 e1001-1003 10.1016/j.surg.2007.09.016 18063088 (Pubitemid 350184107)
10. Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Machens A, Dralle H, Thyroid 2009 19 6 551 554 10.1089/thy.2009.0144 19499987
11. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Vasen HF, van der Feltz M, Raue F, Kruseman AN, Koppeschaar HP, Pieters G, Seif FJ, Blum WF, Lips CJ, Arch Intern Med 1992 152 6 1250 2 10.1001/archinte.1992.00400180104016 1350898
12. Incidence of prominent corneal nerves in multiple endocrine neoplasia type 2A. Kinoshita S, Tanaka F, Ohashi Y, Ikeda M, Takai S, Am J Ophthalmol 1991 111 3 307 11 1672053
13. Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers-the role of Ct serum level. Jarzab B, Szpak-Ulczok S, Krajewska J, Wloch J, Thyroid Research Suppl 2013 6 Suppl 1 9
14. Hirschsprung Disease Consortium: Hirschsprung disease, associated syndromes and genetics: a review. Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, Pelet A, Arnold S, Miao X, Griseri P, Brooks AS, Antinolo G, de Pontual L, Clement-Ziza M, Munnich A, Kashuk C, West K, Wong KK, Lyonnet S, Chakravarti A, Tam PK, Ceccherini I, Hofstra RM, Fernandez R, J Med Genet 2008 45 1 1 14 17965226 (Pubitemid 351158152)
15. Result and summary of voting among audience during presentation and discussion of Medullary Thyroid Carcinoma Clinical Guidelines prepared by American Thyroid Association. Feldt-Rasmussen U, Soderstrom F, Thyroid Research Suppl 2013 6 Suppl 1 12
16. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis. Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K, Sekulla C, Dralle H, Surgery 2008 144 6 1044 50 10.1016/j.surg.2008.08.028 19041016
17. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E, Beck-Peccoz P, Clin Endocrinol (Oxf) 2003 59 2 156 61 10.1046/j.1365-2265.2003. 01782.x (Pubitemid 36918650)
18. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Rothberg AE, Raymond VM, Gruber SB, Sisson J, Thyroid 2009 19 6 651 5 10.1089/thy.2009.0021 19445625
19. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ, J Clin Endocrinol Metab 2001 86 12 5658 71 10.1210/jc.86.12.5658 11739416 (Pubitemid 33152604)